ArticleHaematologica2017
Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.
Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial.BMC health services research · 2023Trial
- Review
- Article
- Feasibility and Implementation of an eHealth Dashboard for the Remote Monitoring of Dutch Patients With Chronic Myeloid Leukemia: Multimethods Approach.JMIR cancer · 2026Article
- Children with chronic-phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML.Haematologica · 2026Article
- Treatment patterns and outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia: a single center study from Oman.Frontiers in oncology · 2026Article
- Treatment response and survival outcomes with BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: a retrospective study.Frontiers in medicine · 2026Article
- Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care.Blood cancer journal · 2025Article
- 5-FU@HFn combined with decitabine induces pyroptosis and enhances antitumor immunotherapy for chronic myeloid leukemia.Journal of nanobiotechnology · 2025Article
- Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2024Review
- Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data.Patient preference and adherence · 2024Article
- Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary.Pathology oncology research : POR · 2024Article
- High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population.Haematologica · 2023Article
- A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia.BMC cancer · 2022Article
- Review
- Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.Annals of hematology · 2022Article
- Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience.Pharmacology research & perspectives · 2022Article
- The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era.Haematologica · 2022Article
- Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.Leukemia · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluations of the 'real-world' efficacy and safety of tyrosine kinase inhibitors in patients with chronic myeloid leukemia are scarce. A nationwide, population-based, chronic myeloid leukemia registry was analyzed to evaluate (deep) response rates to first and subsequent treatment lines and eligibility for a treatment cessation attempt in adults diagnosed between January 2008 and April 2013 in the Netherlands. The registry covered 457 patients; 434 in chronic phase (95%) and 15 (3%) in advanced disease phase. Seventy-five percent of the patients in chronic phase were treated with imatinib and 25% with a second-generation tyrosine kinase inhibitor. At 3 years 44% of patients had discontinued their first-line treatment, mainly due to intolerance (21%) or treatment failure (19%). At 18 months 73% of patients had achieved a complete cytogenetic response and 63% a major molecular response. Deep molecular responses (MR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.